393 related articles for article (PubMed ID: 9219316)
21. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Furst DE; Kolba KS; Fleischmann R; Silverfield J; Greenwald M; Roth S; Hall DB; Roszko PJ;
J Rheumatol; 2002 Mar; 29(3):436-46. PubMed ID: 11908554
[TBL] [Abstract][Full Text] [Related]
22. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
Jick SS
Pharmacotherapy; 2000 Jul; 20(7):741-4. PubMed ID: 10907963
[TBL] [Abstract][Full Text] [Related]
23. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
MacDonald TM; Pettitt D; Lee FH; Schwartz JS
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii3-10. PubMed ID: 14585912
[TBL] [Abstract][Full Text] [Related]
24. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
25. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang DM; Young TH; Hsu CT; Kuo SY; Hsieh TC
Clin Rheumatol; 2001; 20(2):104-13. PubMed ID: 11346221
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
28. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
29. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
Dammann HG
Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
[TBL] [Abstract][Full Text] [Related]
30. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles.
Fenner H
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):28-33. PubMed ID: 9219317
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
32. Meloxicam.
Fleischmann R; Iqbal I; Slobodin G
Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease.
Degner F; Sigmund R; Zeidler H
Clin Ther; 2000 Apr; 22(4):400-10. PubMed ID: 10823362
[TBL] [Abstract][Full Text] [Related]
34. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.
Knijff-Dutmer EA; Kalsbeek-Batenburg EM; Koerts J; van de Laar MA
Rheumatology (Oxford); 2002 Apr; 41(4):458-61. PubMed ID: 11961179
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
[TBL] [Abstract][Full Text] [Related]
36. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
37. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
38. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
Wallace JL
Am J Med; 1999 Dec; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
[TBL] [Abstract][Full Text] [Related]
39. [Meloxicam (Mobic): a review of its pharmacological and clinical profile].
Ogino K; Saito K; Osugi T; Satoh H
Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):391-7. PubMed ID: 12528470
[TBL] [Abstract][Full Text] [Related]
40. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
